Lacosamide Injection
Product Images NDC 13811-207

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 13811-207). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Trigen Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lacosamide Chemical Structure (Lacosamide Injection 1)

Chemical structure of Lacosamide, showing its molecular framework including an amide group, methoxy group, and a phenyl ring.*

FDA Label Image

Figure 1 (Lacosamide Injection 2)

Bar chart titled 'Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose' showing seizure reduction percentages for placebo and different doses of VIMPAT across three studies. The vertical axis represents seizure reduction as median percent change from baseline, ranging from 0% to 45%. Each study compares placebo to multiple VIMPAT doses, with VIMPAT bars showing higher seizure reduction percentages than placebo.*

FDA Label Image

Figure 2 (Lacosamide Injection 3)

A line graph titled 'Figure 2 – Proportion of Patients by Responder Rate for VIMPAT and Placebo Groups in Studies 2, 3, and 4'. The vertical axis represents responder rate (equal to or greater) from -100% (worsening) to 100% (improvement). The horizontal axis indicates percent of patients, decreasing from 100 to 0. Four lines show data for Placebo (N=359) and VIMPAT doses of 200 mg/day (N=267), 400 mg/day (N=466), and 600 mg/day (N=202), depicting cumulative distribution of responder rates across patient groups.*

FDA Label Image

Figure 3 (Lacosamide Injection 4)

Kaplan-Meier analysis graph depicting time to second PGTC seizure comparing placebo (PBO) and Vimpat groups. The y-axis shows the percentage of patients, and the x-axis shows time in days. The graph includes patient numbers at risk over time and statistical results (p-value, hazard ratio, confidence interval) within the plotted data.*

FDA Label Image

Trigen Logo (Lacosamide Injection 5)

FDA Label Image

Lacosamide 200 mg/20 mL Vial Label (Lacosamide Injection 6)

Lacosamide Injection, USP 10 mg/mL concentration in a 20 mL single-dose vial label. The label states it is for intravenous use only, includes a barcode, and has storage instructions to keep at controlled room temperature. Manufactured for Trigen Laboratories, LLC, with location and contact information shown.*

FDA Label Image

Lacosamide 10ct Carton (Lacosamide Injection 7)

The packaging label for Lacosamide Injection, USP contains 200 mg/20 mL (10 mg/mL) strength. It is for intravenous use only and dispensed in 10 single-dose vials of 20 mL each, manufactured by Trigen Laboratories, LLC. The label includes dosing information, storage instructions, a barcode, and placeholder areas for lot and expiration details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.